Andreas Halvorsen acquired 1.81 Million Immunovant shares worth $47.8 Million. That's 0.19% of their equity portfolio (72nd largest holding). The investor owns 1.16% of the outstanding Immunovant stock. The investor's estimated purchase price is $66 Million, resulting in a loss of 28%.